Biofrontera AG - 16 Sep 2025 Form 4 Insider Report for Biofrontera Inc. (BFRI)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BFRI
Reported as of: 16 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Sep 2025, 11:59:26 UTC
Prior SEC filing: 09 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Maria del Pilar de la Huerta Martinez, as Chief Financial Officer of Biofrontera AG

Key filing fact

Biofrontera AG filed Form 4 for Biofrontera Inc. (BFRI) on 18 Sep 2025.

Key facts

This page summarizes Biofrontera AG's Form 4 filing for Biofrontera Inc. (BFRI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Sep 2025, 11:59.

Change

Previous filing in this sequence was filed on 09 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712641 Primary reporting owner

Biofrontera AG

Relationship: Director, 10%+ Owner
Address: HEMMELRATHER WEG 201, LEVERKUSEN, GERMANY
Signature: /s/ Maria del Pilar de la Huerta Martinez, as Chief Financial Officer of Biofrontera AG
Signature date: 18 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BFRI transaction Derivative

Series D Convertible Preferred Stock

Purchase

Transaction value
Shares: +3,019
Change %
Price
Shares after: 3,019
Date: 16 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,831,172
Exercise price: $0.000600
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

Footnote F2

The reporting person acquired the convertible preferred stock in a privately negotiated transaction in exchange for assets related to the production and sale of certain products in the United States having an estimated market value of approximately $3,019,000.

SEC remarks

The Reporting Person has entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.